TWI252756B - Use of a composition comprising formoterol and budesonide for the manufacture of a medicament for the treatment of asthma when needed - Google Patents
Use of a composition comprising formoterol and budesonide for the manufacture of a medicament for the treatment of asthma when needed Download PDFInfo
- Publication number
- TWI252756B TWI252756B TW088109070A TW88109070A TWI252756B TW I252756 B TWI252756 B TW I252756B TW 088109070 A TW088109070 A TW 088109070A TW 88109070 A TW88109070 A TW 88109070A TW I252756 B TWI252756 B TW I252756B
- Authority
- TW
- Taiwan
- Prior art keywords
- micrograms
- formoterol
- scope
- asthma
- budesonide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Description
^252^56 第088109070號專利申請案 中文說明書替換頁(95年元月) 九、發明說明: 本發明範圍 本發明係關於在需要時解除症狀的、組合物的用途,其 含有 (a) 第一活性成分福莫特樂(f〇rm〇ter〇1),其醫藥上可接 文的鹽或溶劑合物或此鹽的溶劑合物;及 (b) 第二活性成分布的松得(budes〇nide) 的混合物;此組合物用以製成藥物以預防或治療急性氣喘 情況及/或間歇性氣喘及/或慢性氣喘發作。本發明還關於 預防或治療急性氣喘情況及/或間歇性氣喘及/或慢性氣喘 發作的方法,此法是藉吸入給予含前述第一及第二活性成 分的組合物。 本發明背景 儘管近年來在對氣喘的了解上已有更多進步,及引入了 更有效的抗氣喘藥物’氣喘仍是了解不多的及未得充分治 療的疾病。在對此病的治療上最近的進步是由於認識到氣 喘是一種慢性發炎疾病所導致。現在的治療以控制症狀和 減少發炎為目標。此等症狀可用β2_腎上腺素能受體激動 劑如叔 丁 % f (terbutaline),舒喘寧(salbutamol),福莫特 樂(formoterol)及舒喘樂(salmeter〇i)所控制。預防性治療 一般是使用類固醇如倍氣美松雙丙酸醋(beclomethasone dipropionate),氟卡松丙酸酯(fluticasone propionate),莫 他松氟酸酯(mometasone furoate)及布的松得 (budesonide) 〇 58434-950120.doc -5 - 1252756 94 Π. U9 雖然已有了現代維持治療,仍然有許多氣喘病人因多種 原因而得不到恰當的治療,對他們的生活品質構成負面打 }。以不同藥物及裝置所作的太過複雜的治療,會導致病 人與醫生間的誤解和溝通問題。常見的現象是不合作。對 病人進订良好教月可能有部分改善,但仍不能完全解決問 題。是以’對氣喘的新而簡單的治療方法會對許多患呼吸 系統疾病’特別是氣喘’的病人有很大幫助。pcT申請案 御削m3及胸98/15號(二者都是發給ab 〇f SWeden的)所建議的於同一裝置内使用布的松得 Ο-de)及福莫特樂(f〇rm〇ter〇i)組合提供一種具有極 仫女王I·生的車乂佳途技以改善現代的氣喘治療。然而,雖然 已有以此、,且口之適當的規則性治療,例如每天二次,許多 病人有時仍會進人較高頻率及嚴重度加劇(severity ΓΓ二Γ°η)之急性情況,此時f要額外的藥物。此類額 Γ樂通常是快速發生作用的^腎上腺素能受體激動 =,^如叔丁喘寧(t咖aline),舒喘寧⑽ 疋以^要第二種藥物,如此一來將备而砧&絲 從性。所以,現在•要錄♦負面地衫響病人的服 治療之簡捷方法要—種處理維持性治療以及急性情況 本發明概述 性=:二=Γ共適宜的組合物用於製造供治療氣喘急 Μ作的^作輕純治叙補充之用途。 更特定地說,根據本 組合物的用途,此組合物含有(、—種需要時解除症狀的 58434-941I08.doc 1252756 第088109070號專利申請案 中文說明書替換頁(95年元月) 、☆ (a)第一活性成分福莫特樂(f〇rm〇ter〇1),其醫藥上可接 又的鹽或溶劑合物或此鹽的溶劑合物,·及 (b)第二活性成分布的松得(budesonide) 的混合物;此組合物用以像j &策 〇用以I成樂物以預防或治療急性氣喘 情況及/或間歇性氣喘及/或慢性氣喘發作。 本發明組合物在需要時之用途是關於該組合物在下述一 或多種情況下之用途·· 0氣17而急性情況,即急性氣喘發作, ii)間歇性氣喘及/或 111)忮性氣喘的短期(發作)急性氣管痙攣。 急性氣喘發作會不規則地出^見,例士 口當曝露於劑,如花 粉季,病毒感染,;^氣,香水或其他劑時,使病人激起 氣喘發作。 本舍明|巳圍包括使用含活性化合物⑷及(b)的組合物, 除了規則性地治療慢性氣喘夕卜,並以相同的活性化合物⑷ 及(b)或-或多種不同的活性化合物,較佳是選自短作用的 β-激動劑,長作用的β_激動劑及糖皮f類@醇,以治療急 性氣喘情況’間歇性氣喘及慢性氣喘發作。 發明人等認為,當病人期望面對引起氣喘的情況,例如 要運動或進入多煙的情況時,即是預防性用途。 本务明另一方面在提供一種需要時預防或治療急性氣喘 情,及/或間歇性氣喘及/或慢性氣喘發作的方法,此法包 藉及、5予病人有效量的組合物,此組合物含有 Ο)第’舌性成分福莫特樂(formoter〇i),其醫藥上可接受的 58434-950120.doc 1252756 弟088109070號專利申請案 中文說明書替換頁(95年元月) 鹽或 >谷劑合物或此鹽的溶劑合物;及 (b)弟一活性成分布的松得(budesonide)的混合物。 根據本發明,現已令人驚奇地發現,此藥物在需要時可 給予氣喘急性發作的病人。 上述論及之先前技藝所推薦的劑量是一天二次。此推薦 的劑i疋考慮到不要給予太高劑量的活性化合物。但本發 明發現此混合物可給予病人如需要的那麼頻繁。 褐莫特樂(formoterol)及布的松得(budes〇nide)組合可用 作救援藥物。症狀的惡化可藉增加藥物的使用以解除症 狀,例如,在症狀加劇時盡早投入額外之類固醇成分以抑 制加重的呼吸道發炎現象。福莫特樂(f〇rm〇ter〇i^々長時間 作用可減少頻繁給藥的麻煩。#需要時使用布的松得 (budesonide)/福莫特樂(f〇rm〇ter〇1)i組合可減少嚴重度加 劇。此種視需要用途(Pro Re Nata,PRN)也可將哪一病人可 純劑量吸入性類固醇控制,而非在增加長效p2_激動劑 前先增加類固醇劑量之預測的困難度減至最低。使用吸入 性糖皮質類固醇繼以過低之維持性劑量之不足治療 treatment)將可藉由本發明之救援性用法或多或少地”自我 校正”("self-corrected”)。此組合之pRN用途將會產生有益 的抗炎效果,即使病人只在救援目的時使用此組合。所 以,對於患呼吸疾病,特別是氣喘(包括過敏情況,例如 發作性氣喘或間歇性氣喘)之病人的治療方法將可使用福 莫特樂(formoterol)/布的松得卬“以⑽“幻組合作維性持治 療’及在視需要基礎上(用以救援目的),例如預防因運動 58434-950120.doc -8 - 1252756 及/或過敏引起的氣喘。 本發明詳述 福莫特樂(formoterol)是可以數種立體異構物存在的化合 物。本發明包括個別的立體異構物及其混合物。本發明包 括幾何異構物’内旋異構物,外消旋異構物,非鏡像立體 異構物及對映異構物,特別是福莫特樂(f〇rm〇ter〇1)R,R 對映異構物。 適宜的福莫特樂(formoterol)生理上的鹽包括衍生自無機 及有機酸的酸加成鹽,如鹽酸鹽,氫溴酸鹽,硫酸鹽,麟 酸鹽’馬來酸鹽,富馬酸鹽,酒石酸鹽,檸檬酸鹽,苯曱 酸鹽,4-甲氧基苯曱酸鹽,2_或冬烴基苯曱酸鹽,4_氯苯 甲酸鹽’對-曱苯磺酸鹽,甲烷磺酸鹽,抗壞血酸鹽,水 揚酸鹽,醋酸鹽,丁二酸鹽,乳酸鹽,戊二酸鹽,葡糖酸 鹽,tncarballylate,烴基_萘_羧酸鹽或油酸鹽。福莫特樂 (formoterol)較佳是以富馬酸鹽的形式以及以此鹽的水合物 形式使用。 本發明也包括含布的松得(budes〇nide)22R表構物作為第 二活性成分的組合物。 福莫特樂(formoterol)(其二水合富馬酸鹽)的適宜單位劑 量是1微克至48微克,較佳是2微克至24微克,更佳是3微 克至12微克。祸莫特樂(f〇rm〇ter〇1)(其二水合富馬酸鹽)的 每曰劑量,包括維持治療,應為丨微克至1〇〇微克,較佳是 2微克至60微克,更佳是3微克至48微克。 布的权得(budesonide)的適宜單位劑量是2〇微克至16〇〇 58434-941108.doc Μ Μ. 09 1252756 微克,較宜是30微克至800微克,較佳是50微克至400微 克更<土疋1⑽被克至200微克。布的松得(budesonide)的 每曰劑量,包括維持治療,應為2〇微克至4800微克,較 佳是30微克至3200微克,更佳是4〇微克至1600微克。特定 的劑量視病人(年齡,性別,體重等),及疾病的嚴重程度 (輕度、中專、嚴重氣喘)而定。 本發明第一活性成分(如福莫特樂)及第二活性成分的莫 耳比較宜是位於以至丨··;!〇〇之範圍,較佳是“至〗··…,更 佳是1:1至1:5 〇。 較佳是此混合物含一或多種醫藥上可接受的添加劑,稀 釋劑或載劑,更佳是於每一劑中其量為5〇微克至4〇〇〇微 克,更佳是其量為100微克至2〇〇〇微克,最佳是其量為1〇〇 微克至1000微克。適宜的添加劑,稀釋劑或載劑的例包括 礼糖’葡聚糖,甘露糖醇或葡萄糖。較佳是用乳糖 是其單水合物。 i 混合物中的一或多種成分可 微粒乾散,最佳是凝集的小微 活性成分(a)或(b)是與稀釋劑 物的形式。本發明所用各成分 製成此等較佳形式。活性成分 米。 以是乾散的形式,更佳是小 粒乾散。或者是,一或多種 ,添加劑或載劑成順序混合 可用精於此技藝者已知方法 的微粒大小較佳是小於1〇微 …藉經口或經鼻吸入完成。此系統 適:由乾散吸入器,加壓計量吸入器或喷霧器給予 田此系統各成分以加壓吸入器給予時,各成分較佳是 58434-941108.doc -10- 1252756 μ粒形。各成分是溶於,或較 人^丄 疋懸净於,液體推進劑混 合物中。可用的推進劑包括氣赢 Η & 载1虱敛屬,烴屬,或氫氟碳 屬。特佳的推進劑是Pl34a(四翕 ^ 、亂乙烷),PI52a(二氟乙烷) 及P22 7(六氟丙烷),此等推進 疋^都疋可單獨或混合使用 的。一般是與一或多種其他推進 延d及/或一或多種界面活 性劑及/或一或多種其他賦形 ^ 〜^ 例如乙醇,滑潤劑,抗 氧化劑及/或安定劑合用。 當本發明系統各成分是以讀器給予時,各成分可以是 霧化的水性懸浮液或溶液,其pH及等張性可作調整,可為 單位劑量或多劑量調配物。 實例 各成分可如下述實例說日月調配,但此等實例並非限制本 發明範圍。 於下述實例中,微粉化是m方式進行,致使每一成 分的微粒大小適於作吸入給予。Turbuhaler(g)*Astn AB的 商標。 實例1 將4.5重ϊ份二水合福莫特樂(f〇rm〇ter〇1)富馬酸鹽與 重量份單水合乳糖混合。用高壓空氣喷射磨將混合物微粉 化,然後用EP-A-7 176 16方法條件化(conditioned)。將8〇重 畺伤被粉化的布的松得(bu(jes〇nide)以低壓噴射磨混合及 均質化方法加於條件化的產物中。然後用£1^冬721331方 法將此混合物團成球狀,裝入Turbuhaler®儲室内。 實例2 58434-941108.doc -11 - 1252756 將9重量份一水合福莫特樂(form〇terol)富馬酸鹽與83 1重 i份單水合乳糖混合。用鬲壓空氣喷射磨將混合物微粉 化,然後用EP-A-717616方法條件化。將16〇重量份微粉化 的布的松得(budesonide)以低壓噴射磨混合及均質化方法 加於條件化的產物中。然後用EP-A-72 133 1方法將此混合 物團成球狀,裝入Turbuhaler®儲室内。 實例3 將6重量份二水合福莫特樂(formoterol)富馬酸鹽與894重 量份單水合乳糖混合。用高壓空氣喷射磨將混合物微粉 化’然後用EP-A-717616方法條件化。將1 〇〇重量份微粉化 的布的松得(budesonide)以低壓喷射磨混合及均質化方法 加於條件化的產物中。然後用EP-A-721331方法將此混合 物團成球狀,裝入Turbuhaler®儲室内。 實例4 將12重量份二水合福莫特樂(f〇rm〇terol)富馬酸鹽與788 重量份單水合乳糖混合。用高壓空氣喷射磨將混合物微粉 化’然後用EP-A-7 1 76 16方法條件化。將200重量份微粉化 的布的松得(budesonide)以低壓喷射磨混合及均質化方法 加於條件化的產物中。然後用EP-A-72133 1方法將此混合 物團成球狀,裝入Turbuhaler®儲室内。 實例5 以固定福莫特樂(formoterol)富馬酸鹽/布的松得 (budesonide)劑量4.5/80微克或4.5/1 60微克每天二次作維持 治療的病人另外使用相同的組合作為救援目的,每天一或 58434-941108.doc 12 1252756 二次’治療散發性的突發症狀,或是在φ 两日寺炉^ _星 期内治療加劇情況,分別用最大每 、〆一 (A r Μ ϊ 為 36/640微克 (4.5/80微克,吸入8次)及36/1280微克(4 5 ^ • /160微克,吸入8 次)。 實例6 患間歇性氣喘病人使用固定福莫特樂(form〇ter〇i)富馬酸 鹽/布的松得(budesonide)混合物作為需要時的唯一藥物, 直至氣喘消失。最大推薦每日劑量是36/64〇微克(45/8〇微 克,吸入8次)及36/1280微克(4.5/16〇微克,吸入8次),使 用期不超過8-120星期。如果此期過後仍有症狀,應考慮 規則維持治療。 58434-941108.doc 13
Claims (1)
- 12527感痧8109〇7〇號專利申請案 中文申請專利範圍替換本(95年元月) 十、申請專利範圍: 種用於製備在需要時用以治療急性氣喘情況及/或間歇 性氣%及/或慢性氣喘發作之藥劑之組合物之用途,其中 該組合物包括 (a) 第’舌性成分福莫特樂(formoterol),其醫藥上可接 受的鹽或溶劑合物或此鹽的溶劑合物;及 (b) 弟一活性成分布的松得(budesonide) 的混合物; 其中作為福莫特樂(formoterol)比布的松得 (budesonide)計算的(“與化)之莫耳比為1:1至1:1〇()。 2.根據申請專利範圍第丨項之用途,其中作為福莫特樂 (formoterol)比布的松得(budes〇nide)計算的(a)與(b)之莫 耳比為1:1至1:7〇。 3 ·根據申請專利範圍第丨或2項之用途,其中第一活性成分 是二水合福莫特樂(formoterol)富馬酸鹽。 4. 根據申請專利範圍第丨或2項之用途,其中第一活性成分 疋福莫特樂(formoterol)的R,r對映體。 5. 根據申請專利範圍第1或2項之用途,其中福莫特樂 (formoterol)的單位劑量位於1微克至48微克範圍内,此 是以二水合福莫特樂(formoterol)富馬酸鹽計算。 6·根據申請專利範圍第5項之用途,其中福莫特樂 (formoterol)的單位劑量位於3微克至12微克範圍内,此 是以二水合福莫特樂(formoterol)富馬酸鹽計算。 Ί,根據申請專利範圍第1或2項之用途,其中福莫特樂 58434-950120.doc Η 1252756 (f〇rm〇ter〇1)的每曰劑量,包括維持治療,位於丨微克至 ⑽微克範圍内,此是以二水合福莫特樂(f〇rm〇ter〇i)t 馬酸鹽計算。 8.根據申請專利範圍第7項之用途,其中福莫特樂 (f〇rm〇ter〇1)的每曰劑量,包括維持治療,位於2微克至 60微克範圍内,此是以二水合福莫特樂(加讀⑽富馬 酸鹽計算。 9.減巾請專利範圍第丨或2項之用途,其中第三活性成分 是布的松得(budesonide)22R表構物。 1〇·根據中請專利範圍第丨或2項之用途,其中布的松得 (budesonide)單位劑量位於2〇微克至丨6〇〇微克範圍内。 Η.根據申請專利範圍第10項之用途,其中布的松得 (budesonide)單位劑量位於5〇微克至4〇〇微克。 12.根據申請專利範圍第}或2項之用途,其中布的松得 (budesonide)的每日劑量,包括維持治療,位於2克至 4800微克範圍内。 13.根據申請專利範圍第12項之用冑,其中布的松得 (budesonide)的每日劑量’包括維持治療,位於3〇微克至 3200微克範圍内。 14. 根據申請專利範圍第⑷項之用途,其中活性成分⑷及 (b)的微粒大小是小於1〇微米。 15. 根據申請專利範圍第項之用途,其中此組合物還含有 ―或多種醫藥上可接受的添加劑,稀釋劑或載劑。 lit申請專利範圍第15項之用途,其中醫藥上可接受的 -2 - 1252756 添加劑,稀釋劑或載劑是單水合乳糖。 58434-950120.doc
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9802073A SE9802073D0 (sv) | 1998-06-11 | 1998-06-11 | New use |
Publications (1)
Publication Number | Publication Date |
---|---|
TWI252756B true TWI252756B (en) | 2006-04-11 |
Family
ID=20411658
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW088109070A TWI252756B (en) | 1998-06-11 | 1999-06-01 | Use of a composition comprising formoterol and budesonide for the manufacture of a medicament for the treatment of asthma when needed |
Country Status (35)
Country | Link |
---|---|
US (2) | US20010049396A1 (zh) |
EP (3) | EP1085877B1 (zh) |
JP (1) | JP2002517450A (zh) |
KR (1) | KR20010052721A (zh) |
CN (1) | CN100389771C (zh) |
AR (1) | AR018410A1 (zh) |
AT (1) | ATE389409T1 (zh) |
AU (1) | AU771715B2 (zh) |
BR (1) | BR9911073A (zh) |
CA (1) | CA2334411C (zh) |
CY (1) | CY1110376T1 (zh) |
CZ (1) | CZ300874B6 (zh) |
DE (1) | DE69938390T2 (zh) |
DK (1) | DK1085877T3 (zh) |
EE (1) | EE05661B1 (zh) |
ES (1) | ES2302384T3 (zh) |
HK (1) | HK1035145A1 (zh) |
HU (1) | HUP0103108A3 (zh) |
ID (1) | ID27937A (zh) |
IL (2) | IL139921A0 (zh) |
IS (1) | IS5752A (zh) |
MY (1) | MY129281A (zh) |
NO (3) | NO20006253L (zh) |
NZ (1) | NZ536279A (zh) |
PL (1) | PL344665A1 (zh) |
PT (1) | PT1085877E (zh) |
RU (1) | RU2222332C2 (zh) |
SA (1) | SA99200234B1 (zh) |
SE (1) | SE9802073D0 (zh) |
SK (1) | SK286252B6 (zh) |
TR (1) | TR200003666T2 (zh) |
TW (1) | TWI252756B (zh) |
UA (1) | UA87956C2 (zh) |
WO (1) | WO1999064014A1 (zh) |
ZA (1) | ZA200006943B (zh) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9703407D0 (sv) | 1997-09-19 | 1997-09-19 | Astra Ab | New use |
SE9802073D0 (sv) | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
DZ2947A1 (fr) | 1998-11-25 | 2004-03-15 | Chiesi Farma Spa | Inhalateur à compteur de dose sous pression. |
US6004537A (en) * | 1998-12-18 | 1999-12-21 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol |
IT1313553B1 (it) | 1999-07-23 | 2002-09-09 | Chiesi Farma Spa | Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione. |
IT1317846B1 (it) | 2000-02-22 | 2003-07-15 | Chiesi Farma Spa | Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva. |
GB0009584D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Pharmaceutical compositions |
IT1318514B1 (it) * | 2000-05-12 | 2003-08-27 | Chiesi Farma Spa | Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari. |
GB0012261D0 (en) * | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel process |
GB0012260D0 (en) | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel composition |
ME00220B (me) | 2000-05-22 | 2010-10-10 | Chiesi Farm Spa | Stabilne farmaceutske formulacije rastvora za inhalatore odmjerene doze pod pritiskom |
TR200401980T4 (tr) | 2001-07-02 | 2004-09-21 | Chiesi Farmaceutici S.P.A. | Aerosol olarak uygulama için en uygun hale getirilmiş tobramisin formülasyonu |
GB0208742D0 (en) | 2002-04-17 | 2002-05-29 | Bradford Particle Design Ltd | Particulate materials |
EP1446104B2 (en) * | 2001-11-01 | 2011-08-03 | Novartis AG | Spray drying methods |
FI20020126A0 (fi) * | 2002-01-23 | 2002-01-23 | Orion Corp | Koostumuksia pulmonaaliseen antoon |
SE0200312D0 (sv) * | 2002-02-01 | 2002-02-01 | Astrazeneca Ab | Novel composition |
US9339459B2 (en) | 2003-04-24 | 2016-05-17 | Nektar Therapeutics | Particulate materials |
GB0219512D0 (en) * | 2002-08-21 | 2002-10-02 | Norton Healthcare Ltd | Inhalation compositions with high drug ratios |
GB0219511D0 (en) | 2002-08-21 | 2002-10-02 | Norton Healthcare Ltd | Method of preparing dry powder inhalation compositions |
JP4744876B2 (ja) * | 2002-08-21 | 2011-08-10 | ノートン・ヘルスケアー リミテッド | 乾燥粉末吸入組成物の製造方法 |
TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
EP1595531A1 (en) | 2004-05-13 | 2005-11-16 | CHIESI FARMACEUTICI S.p.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
US20050207983A1 (en) | 2004-03-05 | 2005-09-22 | Pulmatrix, Inc. | Formulations decreasing particle exhalation |
US20070098644A1 (en) * | 2005-10-31 | 2007-05-03 | Richie's Pharmacy And Medical Supply, Incorporated | Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease |
GB0604141D0 (en) * | 2006-03-01 | 2006-04-12 | Arrow Int Ltd | Nebulizer formulation |
KR20090129998A (ko) | 2007-02-11 | 2009-12-17 | 맵 파마슈티컬스, 인코포레이티드 | 부작용 프로파일을 최소화하면서 편두통의 빠른 완화를 가능하게 하는 dhe의 치료적 투여 방법 |
EP2124915A2 (en) | 2007-02-19 | 2009-12-02 | Cipla Limited | Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid |
EP1982709A1 (en) * | 2007-04-19 | 2008-10-22 | CHIESI FARMACEUTICI S.p.A. | Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma |
CN107412212B (zh) | 2009-05-29 | 2021-01-22 | 珍珠治疗公司 | 经肺递送长效毒蕈碱拮抗剂及长效β2肾上腺素能受体激动剂的组合物及相关方法与系统 |
PL2538922T3 (pl) * | 2010-02-25 | 2016-11-30 | Formułowanie kompozycji do leczenia stanów zapalnych | |
WO2012007729A2 (en) * | 2010-07-16 | 2012-01-19 | Cipla Limited | Pharmaceutical compositions |
EP2448571B1 (en) | 2010-08-30 | 2013-06-12 | Pulmatrix, Inc. | Respirably dry powder comprising calcium lactate, sodium chloride and leucine |
EP2611438B1 (en) | 2010-08-30 | 2020-04-01 | Pulmatrix Operating Company, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
CN102416179B (zh) | 2010-09-28 | 2014-05-07 | 益得生物科技股份有限公司 | 用于哮喘的吸入性复方组合物 |
DK3470057T3 (da) | 2010-09-29 | 2021-11-22 | Pulmatrix Operating Co Inc | Kationiske tørpulvere omfattende magnesiumsalt |
MX354828B (es) | 2010-09-29 | 2018-03-22 | Pulmatrix Operating Co Inc | Polvos secos de cationes metálicos monovalentes para inhalación. |
JOP20120023B1 (ar) * | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
CN107596518B (zh) | 2012-02-29 | 2021-04-23 | 普马特里克斯营业公司 | 可吸入干粉剂 |
RU2504382C1 (ru) * | 2012-06-13 | 2014-01-20 | Шолекс Девелопмент Гмбх | Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения |
WO2014165303A1 (en) | 2013-04-01 | 2014-10-09 | Pulmatrix, Inc. | Tiotropium dry powders |
ITMI20130571A1 (it) | 2013-04-10 | 2014-10-11 | Zambon Spa | Composizione farmaceutica contenente budesonide e formoterolo |
GB201408387D0 (en) * | 2014-05-12 | 2014-06-25 | Teva Pharmaceuticals Europ B V | Treatment of respiratory disorders |
TW201735914A (zh) * | 2015-12-22 | 2017-10-16 | 阿斯特捷利康公司 | 用於治療慢性阻塞性肺疾病之醫藥組成物 |
IT202000006442A1 (it) | 2020-03-27 | 2021-09-27 | Genetic S P A | Budesonide 21-phosphate salts and pharmaceutical compositions containing the same |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4203401A (en) | 1979-01-29 | 1980-05-20 | General Motors Corporation | Evaporative emissions canister |
DK0416950T3 (da) | 1989-09-08 | 1993-10-11 | Glaxo Group Ltd | Medikamenter |
IL95590A (en) | 1989-09-08 | 1996-06-18 | Glaxo Group Ltd | Medicinal preparations containing Salmetrol and Pluticasone Propionate |
US5250286A (en) * | 1990-05-07 | 1993-10-05 | Aegis Technology, Inc. | Treatment of chronic obstructive pulmonary disease (COPD) by inhalation of an imidazoline |
PL164294B1 (pl) | 1990-12-20 | 1994-07-29 | Inst Farmaceutyczny | Sposób otrzymywania diastereoizomeru /22R/-16a , 17a-butylidenodioksy-11 ß 21-dihydroksy-1,4-pregnadien-3,20-dionu PL |
US5795564A (en) * | 1991-04-05 | 1998-08-18 | Sepracor, Inc. | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol |
SE9302777D0 (sv) | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
US5119791A (en) | 1991-06-07 | 1992-06-09 | General Motors Corporation | Vapor storage canister with liquid trap |
US5444521A (en) | 1991-07-15 | 1995-08-22 | Canon Kabushiki Kaisha | Image fixing device capable of controlling heating overshoot |
AU673660C (en) * | 1991-12-18 | 2002-07-25 | Astrazeneca Ab | New combination of formoterol and budesonide |
EP1086697A2 (en) | 1991-12-18 | 2001-03-28 | AstraZeneca AB | New combination of formoterol and budesonide |
US5408977A (en) | 1993-08-23 | 1995-04-25 | Walbro Corporation | Fuel tank with carbon canister and shut-off valve |
BR9407686A (pt) | 1993-10-01 | 1997-02-04 | Astra Ab | Processo e aparelho para o tratamento de um medicamento em pó finamente dividido uso do aparelho e aglomerados |
SE9404080L (sv) * | 1993-12-28 | 1995-06-29 | Ciba Geigy Ag | Förfarande för framställning av en optiskt ren enantiomer av formoterol |
US5511957A (en) | 1994-09-27 | 1996-04-30 | Walbro Corporation | High capacity fuel pump and filter combination |
SE9700134D0 (sv) | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
US5983956A (en) * | 1994-10-03 | 1999-11-16 | Astra Aktiebolag | Formulation for inhalation |
GB9519692D0 (en) * | 1995-09-27 | 1995-11-29 | Quillin Helen | Atomising nozzle |
US6277862B1 (en) | 1995-11-24 | 2001-08-21 | Smithkline Beecham S.P.A. | Quinoline derivatives |
US5651349A (en) | 1995-12-11 | 1997-07-29 | Chrysler Corporation | Purge system flow monitor and method |
SE9603669D0 (sv) | 1996-10-08 | 1996-10-08 | Astra Ab | New combination |
SE9700135D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
SK184799A3 (en) | 1997-06-27 | 2000-06-12 | Astra Ab | New combination of antiasthma medicaments |
SE9703407D0 (sv) * | 1997-09-19 | 1997-09-19 | Astra Ab | New use |
US6598603B1 (en) * | 1997-12-31 | 2003-07-29 | Astra Aktiebolag | Method for treating respiratory diseases |
SE9802073D0 (sv) | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
US5957114A (en) | 1998-07-17 | 1999-09-28 | Ford Motor Company | Evaporative emission canister for an automotive vehicle |
US5924410A (en) | 1998-07-20 | 1999-07-20 | Ford Motor Company | Evaporative emission canister for an automotive vehicle |
DZ2947A1 (fr) | 1998-11-25 | 2004-03-15 | Chiesi Farma Spa | Inhalateur à compteur de dose sous pression. |
US6004537A (en) | 1998-12-18 | 1999-12-21 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol |
US6227862B1 (en) * | 1999-02-12 | 2001-05-08 | Advanced Drivers Education Products And Training, Inc. | Driver training system |
DE60016990T2 (de) | 1999-02-26 | 2005-12-29 | Walbro Corp., Cass City | Fahrzeugbrennstoffsystem |
SE9900834D0 (sv) | 1999-03-09 | 1999-03-09 | Astra Ab | Novel combination |
US6237574B1 (en) | 1999-04-20 | 2001-05-29 | Ford Motor Company | Evaporative emission canister for an automotive vehicle |
US6136075A (en) | 1999-05-03 | 2000-10-24 | Westvaco Corporation | Automotive evaporative emissions canister adsorptive restraint system |
JP3646217B2 (ja) | 1999-07-08 | 2005-05-11 | 愛三工業株式会社 | キャニスタモジュール |
US6374811B1 (en) | 2000-10-04 | 2002-04-23 | Ford Global Technologies, Inc. | System and method for minimizing fuel evaporative emissions from an internal combustion engine |
-
1998
- 1998-06-11 SE SE9802073A patent/SE9802073D0/xx unknown
-
1999
- 1999-05-28 AR ARP990102532A patent/AR018410A1/es unknown
- 1999-06-01 TW TW088109070A patent/TWI252756B/zh not_active IP Right Cessation
- 1999-06-09 SA SA99200234A patent/SA99200234B1/ar unknown
- 1999-06-09 MY MYPI99002351A patent/MY129281A/en unknown
- 1999-06-10 DK DK99930103T patent/DK1085877T3/da active
- 1999-06-10 UA UA2000126983A patent/UA87956C2/uk unknown
- 1999-06-10 KR KR1020007013993A patent/KR20010052721A/ko not_active Application Discontinuation
- 1999-06-10 CN CNB998072303A patent/CN100389771C/zh not_active Expired - Lifetime
- 1999-06-10 TR TR2000/03666T patent/TR200003666T2/xx unknown
- 1999-06-10 DE DE69938390T patent/DE69938390T2/de not_active Expired - Lifetime
- 1999-06-10 PL PL99344665A patent/PL344665A1/xx unknown
- 1999-06-10 ES ES99930103T patent/ES2302384T3/es not_active Expired - Lifetime
- 1999-06-10 SK SK1888-2000A patent/SK286252B6/sk not_active IP Right Cessation
- 1999-06-10 PT PT99930103T patent/PT1085877E/pt unknown
- 1999-06-10 US US09/367,950 patent/US20010049396A1/en not_active Abandoned
- 1999-06-10 AT AT99930103T patent/ATE389409T1/de active
- 1999-06-10 BR BR9911073-3A patent/BR9911073A/pt not_active Application Discontinuation
- 1999-06-10 EP EP99930103A patent/EP1085877B1/en not_active Revoked
- 1999-06-10 CZ CZ20004593A patent/CZ300874B6/cs not_active IP Right Cessation
- 1999-06-10 ID IDW20002566A patent/ID27937A/id unknown
- 1999-06-10 CA CA002334411A patent/CA2334411C/en not_active Expired - Lifetime
- 1999-06-10 EP EP03002381A patent/EP1316311A1/en not_active Withdrawn
- 1999-06-10 HU HU0103108A patent/HUP0103108A3/hu unknown
- 1999-06-10 AU AU46710/99A patent/AU771715B2/en not_active Expired
- 1999-06-10 NZ NZ536279A patent/NZ536279A/en not_active IP Right Cessation
- 1999-06-10 IL IL13992199A patent/IL139921A0/xx active IP Right Grant
- 1999-06-10 JP JP2000553082A patent/JP2002517450A/ja active Pending
- 1999-06-10 WO PCT/SE1999/001031 patent/WO1999064014A1/en not_active Application Discontinuation
- 1999-06-10 RU RU2000131218/14A patent/RU2222332C2/ru not_active IP Right Cessation
- 1999-06-10 EE EEP200000740A patent/EE05661B1/xx unknown
- 1999-06-10 EP EP10178172A patent/EP2266574A1/en not_active Withdrawn
-
2000
- 2000-11-27 ZA ZA200006943A patent/ZA200006943B/en unknown
- 2000-11-27 IL IL139921A patent/IL139921A/en not_active IP Right Cessation
- 2000-12-05 IS IS5752A patent/IS5752A/is unknown
- 2000-12-08 NO NO20006253A patent/NO20006253L/no not_active Application Discontinuation
-
2001
- 2001-08-17 HK HK01105814A patent/HK1035145A1/xx not_active IP Right Cessation
-
2003
- 2003-09-19 US US10/665,240 patent/US9295644B2/en active Active
-
2008
- 2008-05-13 CY CY20081100507T patent/CY1110376T1/el unknown
-
2013
- 2013-02-18 NO NO20130269A patent/NO20130269L/no not_active Application Discontinuation
-
2014
- 2014-06-27 NO NO20140823A patent/NO20140823L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI252756B (en) | Use of a composition comprising formoterol and budesonide for the manufacture of a medicament for the treatment of asthma when needed | |
US9446054B2 (en) | Pharmaceutical products and composition comprising specific anticholinergic agents, β-2 agonists and corticosteroids | |
TW474823B (en) | Powder formulations containing, as a diluent, D-melezitose (Α-D-melezitose), β-D-glucopyranoside, O-Α-D-glucopyranosyl-1,3-β-D-fructofuranosyl (β-D-melezitose) or isomelezitose | |
TW470647B (en) | Composition and pharmaceutical combination kit comprising formoterol and budesonide | |
TW562676B (en) | Liquid formulation with formoterol, suitable for storage | |
US20040198708A1 (en) | Formulations of mometasone and a bronchodilator for pulmonary administration | |
KR20110045004A (ko) | 충혈제거제 및 코르티코스테로이드를 포함하는 비강내 조성물 | |
CN105412122A (zh) | 包含r(+)布地奈德和一种或多种支气管扩张剂的药物组合物 | |
US20090246281A1 (en) | Soft steroid compositions for use in dry powder inhalers | |
US20090118249A1 (en) | Dheas inhalation compositions | |
WO2019091082A1 (zh) | 一种羧甲司坦雾化吸入用溶液制剂及其制备方法 | |
CN104271112A (zh) | 包含阿福特罗和糠酸氟替卡松的药物组合物 | |
US20220192978A1 (en) | Pharmaceutical Inhalation Aerosol and Preparation Method Therefor | |
CN115463117A (zh) | 一种递送效率高的布地奈德沙丁胺醇复方雾化吸入混悬液及其制备方法 | |
MXPA00011806A (en) | Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4A | Expiration of patent term of an invention patent |